Clinical Trial

A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Pancreatic cancer is an extremely high-mortality malignancy. The chemotherapy regimen of gemcitabine combined with nab-paclitaxel (GEM-NABP) serves as one of the first-line standard therapies for metastatic pancreatic cancer. Given that traditional dual HER2 blockade (pertuzumab + trastuzumab) has demonstrated preliminary efficacy in HER2-expressing solid tumors, the novel clinical strategy of dual HER2 blockade (HLX22 + trastuzumab) combined with GEM-NAP offers the potential to improve outcomes for patients with HER2-positive pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-09.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-27
Trial Details
NCT Number NCT07176702
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Metastatic PDAC, HER2-positive Status
Enrollment 45 participants
Start Date 2025-09-30
Primary Completion 2027-03-05 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-05